Breast Cancer Metastasis: Is a Common Inherited Gene Variant Responsible?

New researchhas shown that breast cancer metastasis risk may be linked to a person's inherited genetic makeup. This suggests a fundamental shift in cancer biology: metastasis may result not only from tumor cells but also from the host's genetic background.

🧬 Unlocking Breast Cancer Metastasis: An Inherited Genetic Variant?

Despite advances in early detection, surgery, systemic treatment, and immunotherapy, metastatic recurrence remains a major breast cancer risk. For decades, scientists focused on somatic mutations within tumor cells to explain metastasis—we studied the seed. A groundbreaking study published in 2025 in Cell turns attention elsewhere. Perhaps the real problem lies in the soil: the patient’s inherited genetic background.

🧪 Study Design

Using a multilayered methodology , this groundbreaking study showed how an inherited genetic variant affects breast cancer metastasis. It had three main stages:

1. Clinical Cohort Data:

• Genetic and clinical data from a large Swedish early-stage breast cancer cohort were analyzed.
• The genetic change examined was in PCSK9 : the rs562556 (V474I) variant.
• Patients were classified according to the rs562556 (V474I) variant.
• After 15 years of follow-up,patients carrying the change on both chromosomes (homozygotes) had a distant metastasis risk of 22% , compared with 2% in noncarriers. This genetic variation could therefore affect the course of breast cancer by up to 11-fold .

2. Genetic Functional Analysis in Mice:

• To understand the human variant's function, researchers generated transgenic mice carrying two different versions of PCSK9 :
  • hPCSK9^474Val/Val (normal)
  • hPCSK9^474Ile/Ile (variant)
• Breast cancer cells were injected into these mice, and metastasis was observed.
• Mice carrying the variant showed substantially greater frequency and extent of lung metastases .

3. Analysis of the Molecular Mechanism:

• Experiments investigating how the PCSK9 V474I variant increases metastasis showed that it suppresses LRP1, a receptor protein on tumor-cell surfaces .
• When LRP1 is suppressed, XAF1 and USP18 , genes that normally inhibit metastasis, are silenced.
• This increases tumor cells' metastatic capacity.

💊 A Treatment Opportunity: PCSK9 Inhibitors in Oncology?

The PCSK9 gene product is a protein involved in cholesterol metabolism and can be inhibited by FDA-approved drugs such as evolocumab . Mouse experiments provided early evidence that these inhibitors may suppress metastasis. The team aims to launch prophylactic (preventive) clinical trials in high-risk patients.

🧠 Redefining Metastasis: "It May Be an Inherited Disease"

Lead author Dr. Sohail Tavazoie says: "For all these years we have studied the seed—the tumor. But the real problem may be in the soil.”

This emphasizes that cancer is shaped not only by intracellular mutations but also by host factors such as immunity, metabolism, and the tissue microenvironment.

🔍 Could This Apply to Other Cancers?

An earlier melanoma study showed worse survival in carriers of the APOE2 variant. This suggests an inherited genetic basis for metastatic tendency may extend beyond breast cancer to other tumor types.

🧭 Clinical and Social Implications

• Should genetic analyses target not only the tumor but also germline (inherited) genetics ?
• Could high-risk individuals enter metastasis-prevention strategies earlier?
• Should personalized oncology be reshaped around inherited risks?

🔚 Conclusion: At the Threshold of a New Understanding of Metastasis

These PCSK9 findings suggest inherited factors can shape metastasis and allow more personalized prevention. Although clinical application will take time, such studies may bring "germline-targeted metastasis prevention" into focus.